Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- A ...

The FDA approved the travoprost intracameral implant (iDose TR) for treatment of ocular hypertension and glaucoma, device developer Glaukos announced on Thursday. The implant is designed to provide ...

Please provide your email address to receive an email when new articles are posted on . Timolol maleate 0.5% microdrops delivered with a volume-reducing adaptor provided noninferior IOP reduction ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with glaucoma showed a 50% reduction in IOP ...

Compr Ophthalmol Update. 2005;6(2):85-101. In summary, the aqueous suppressors timolol gel once daily and brinzolamide are recommended first-line glaucoma agents often used together, with timolol gel ...

To reduce elevated intraocular pressure (IOP) in glaucoma or ocular hypertension where adjunctive or replacement therapy is warranted. Combigan contains two drugs widely used in the treatment of ...

If people with glaucoma don't stay on top of their condition, blindness may result. An experimental new contact lens is designed to help, by both monitoring glaucoma symptoms and automatically ...

EyeD Pharma’s new spin on an old molecule has attracted investor support, giving it 45 million euros ($51 million) to advance an implant that could challenge AbbVie for the glaucoma market. In 2020, ...